Vasculitis Lupus
Conditions
Brief summary
Systemic lupus erythematosus (SLE) is a complex heterogeneous autoimmune disease with a wide variety of clinical and serological manifestations that may affect any organ. Vasculitis prevalence in SLE is reported to be between 11% and 36%.
Detailed description
Systemic lupus erythematosus (SLE) is a complex heterogeneous autoimmune disease with a wide variety of clinical and serological manifestations that may affect any organ. Vasculitis prevalence in SLE is reported to be between 11% and 36%. A diverse clinical spectrum, due to inflammatory involvement of vessels of all sizes, is present. Even though cutaneous lesions, representing small vessel involvement, are the most frequent, medium and large vessel vasculitis may present with visceral affection, with life-threatening manifestations such as mesenteric vasculitis, pulmonary hemorrhage, or mononeuritis multiplex, with detrimental consequences. Early recognition and an appropriate treatment are crucial. Recent studies have shown that vasculitis in patients with SLE may present different clinical forms based on the organ involved and the size of the affected vessel. It is noteworthy that the episodes of vasculitis are not always accompanied by high disease activity. Recent articles on this topic have focused on new treatments for the control of vascular disease, such as biological therapies such as Rituximab and Belimumab, among others.
Interventions
OTHERVasculitis In SLE
20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
Sponsors
Tabarak New Cairo Hospital (TNCH)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
22 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* LE or suspected SLE established by ACR criteria * Ability to give informed consent * Adult and minor relatives (first and second degree) of individuals Included in IV-G (only for genetic studies) * Ability of the patient or minor relative s parents to give informed consent * Affected individuals age greater than or equal to 9 years with no upper age limit * Healthy Volunteers (non-related) age greater than or equal to 18 with no upper age limit * Healthy Volunteers (first- and second-degree relatives) age greater than or equal to 9 with no upper age limit * Vascular studies adults only age greater than or equal to 18 with no upper age limit
Exclusion criteria
* Concomitant medical problems which would confound the interpretation of studies gathered by this protocol. Included in this is the presence of HIV in the blood, active malignancies, or other significant medical conditions that may interferes with interpretation of some lupus studies. * Concomitant medical, surgical or other conditions for which inadequate facilities are available to support their care at NIH. Inability or unwillingness to comply with follow up requirements (e.g. distance, social, physical limitations) * Any comorbidity of medical or psychological/psychiatric condition or treatment after reviewing of patients previous or outside medical records, that in the opinion of the Principal Investigator, would exclude the subjects from the research studies (e.g. Patient requiring urgent and/or acute medical care, surgical or other procedures) * Unwilling to participate in research studies or to provide research samples or data. Criteria for exclusion: \- Any concomitant medical problems or are taking medications which would confound the interpretation of studies they are considered for
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SLE Vasculitis | 6 months | Incidence of vasculitic pattern |
Countries
Egypt
Contacts
Primary ContactTayseer A Abdulaal, M.D.
Outcome results
None listed